Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Omnicell Inc(OMCL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OMCL
10/23/2026: OMCL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Omnicell Inc is a healthcare technology firm specializing in medication management and pharmacy automation for hospital and health systems. The company is known for its extensive installed base of dispensing cabinets and a growing cloud-based software portfolio that generates recurring revenue. Its primary growth opportunity lies in the transition of hospitals toward fully autonomous, digital pharmacy workflows. However, the company faces risks from heavy dependence on hospital capital expenditure budgets, competitive pressure from established medical device incumbents, and execution challenges. The stock may best suit growth-oriented investors who are comfortable with the inherent volatility of the healthcare technology sector and who will monitor the company's progress on shifting toward a software-centric subscription model.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in a secularly growing healthcare automation space. |
| Momentum investor | Mixed fit | This is conditional on a positive trend in hospital capital expenditure cycles. |
| Value investor | Mixed fit | Valuation fluctuates significantly based on perceived long-term growth prospects. |
| Dividend investor | Weak fit | The company does not pay a dividend, prioritizing growth reinvestment. |
| Low-risk investor | Weak fit | The stock exhibits high volatility sensitive to healthcare sector macro trends. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings based on quarterly hospital sales reports. |
| Valuation risk | Medium / high | Growth expectations are often priced into the stock, leaving room for downside on misses. |
| Competition risk (BDX competition) | High | Dominant competitors can pressure pricing and market share in the core dispensing cabinet segment. |
| Business quality | Medium | While sticky, the business is highly dependent on institutional capital spending. |
| Dividend income | Low / none | Investors receive zero yield, which may not suit income-focused portfolios. |
| Execution risk | Medium | Successfully transitioning legacy hardware customers to software platforms is complex. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -11.7% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.72B USD | Price to earnings Ratio 44.94 | 1Y Target Price 57.86 |
Price to earnings Ratio 44.94 | 1Y Target Price 57.86 | ||
Volume (30-day avg) 491.8K shares | Beta 0.99 | 52 Weeks Range 29.09 - 55.00 | Updated Date 10/24/2026 |
52 Weeks Range 29.09 - 55.00 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Automation and Analytics | Dispensing cabinets, central pharmacy robots, and subscription software. | The core of the business—hospitals pay for both the hardware and the software that runs their pharmacy. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 0.24 | Actual - |
Profitability
Profit Margin 3.14% | Operating Margin (TTM) 5.91% |
Management Effectiveness
Return on Assets (TTM) 1.52% | Return on Equity (TTM) 3.06% |
Valuation
Trailing PE 44.94 | Forward PE 29.5 | Enterprise Value 1.41B | Price to Sales(TTM) 1.38 |
Enterprise Value 1.41B | Price to Sales(TTM) 1.38 | ||
Enterprise Value to Revenue 1.13 | Enterprise Value to EBITDA 9.87 | Shares Outstanding 45.48M | Shares Floating 44.38M |
Shares Outstanding 45.48M | Shares Floating 44.38M | ||
Percent Insiders 2.15 | Percent Institutions 109.17 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.